Learn What ENBREL Can Do Sucks Customer Reviews and Feedback
Etanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.
A sad consumer writes "BEWARE OF THIS DRUG! After long standing Rheumatoid arthritis, I tried Enbrel for 1 year. It seemed to help in the first two months, then it stopping working. I subsequently developed severe blood infections, vision problems, severe non-healing wounds, nervous system disorders. I have been hospitalized for almost 1 year now. Prior to taking this drug, my arthritis was the only health problem I had. I had no other conditions or history of infection. All this occurred after taking this drug. I am not alone; look into the warnings before taking this drug!".
In The News
Chicago Tribune reports"Drugmaker AbbVie will pay $24 million to settle fraud lawsuit over Humira marketing"
Law360 reports"Sandoz Warns Fed. Circ. Enbrel Ruling Invites Patent Abuse"
FiercePharma reports"Copycats hurt Amgen in 2019. Can Otezla, new launches ease the pain?"
Lexology reports"AbbVie's Enforcement of its 'Patent Thicket' For Humira Under the BPCIA Does Not Provide Cognizable Basis for an Antitrust Violation"